Zentalis Pharmaceuticals

ZNTLNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$291.579 M

$3.08 +1.65%

Close of 22 Sept 2026

Revenue

$0.00

#3637 by revenue

Earnings

-$137.1M

Loss-making

Shares outstanding

71,671,914

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#237ImmuneeringIMRX$298.3M
#238Fulcrum TherapeuticsFULC$293.0M
#239Zentalis PharmaceuticalsZNTL$291.6M
#240AmarinAMRN$290.4M
#241Greenwich LifeSciencesGLSI$285.9M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Zentalis Pharmaceuticals, worth $15.2M. Grants and option exercises are excluded.

WALTERS GROUP, Susan Berkley Walters, William Thurman Walters$15.2M
4,335,000 shares at $3.50 on 14 Aug 2026 · filed 19 Aug 2026

What if Zentalis Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.2T

$319,366.51

Per share 103,690× higher

Bitcoin $1.74T

$18,397.40

Per share 5,973× higher

Nvidia $5.52T

$58,263.97

Per share 18,917× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Zentalis Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.